Structure and expression of different serum amyloid a (saa) variants and their concentration-dependent functions during host insults

Current Medicinal Chemistry

Volumn 23, Issue 17, 2016, Pages 1725-1755

  De Buck, Mieke ^a   Gouwy, Mieke ^a   Wang, Ji Ming ^b   Van Snick, Jacques ^c,d   Opdenakker, Ghislain ^a   Struyf, Sofie ^a   Van Damme, Jo ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^b NATIONAL CANCER INSTITUTE   (United States)

^c LUDWIG INSTITUTE FOR CANCER RESEARCH   (Belgium)

^d DE DUVE INSTITUTE   (Belgium)

Author keywords

Amyloidosis; Chemotaxis; Cytokines; FPR2; Inflammatory diseases; Leukocytes; Saa variants; TLR2

Indexed keywords

CHEMOATTRACTANT; CHEMOKINE; ENZYME; G PROTEIN COUPLED RECEPTOR; PROTEIN VARIANT; RECEPTOR; SERUM AMYLOID A; SERUM AMYLOID A 1; SERUM AMYLOID A 2; SERUM AMYLOID A 4; SERUM AMYLOID A RECEPTOR; TOLL LIKE RECEPTOR; UNCLASSIFIED DRUG;

AMYLOID A AMYLOIDOSIS; AMYLOIDOSIS; ANTIINFLAMMATORY ACTIVITY; ARTICLE; ATHEROSCLEROSIS; BIOLOGICAL FUNCTIONS; CHRONIC DISEASE; DRUG DESIGN; GENE STRUCTURE; HUMAN; LUNG DISEASE; MALIGNANT NEOPLASTIC DISEASE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; OBESITY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN STRUCTURE; RHEUMATOID ARTHRITIS; TRANSFORMED CELL; CHEMISTRY; GENETIC VARIATION; GENETICS; METABOLISM;

GENOMIC STRUCTURAL VARIATION; HUMANS; SERUM AMYLOID A PROTEIN;

EID: 84975509489     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/0929867323666160418114600     Document Type: Article

References (246)

1. Rosenthal, C.J.; Franklin, E.C. Variation with age and disease of an amyloid A protein-related serum component. J. Clin. Invest., 1975, 55(4), 746-753.
2. Shainkin-Kestenbaum, R.; Winikoff, Y.; Cristal, N. Serum amyloid A concentrations during the course of acute ischaemic heart disease. J. Clin. Pathol., 1986, 39(6), 635-637.
3. Kluve-Beckerman, B.; Naylor, S.L.; Marshall, A.; Gardner, J.C.; Shows, T.B.; Benson, M.D. Localization of human SAA gene(s) to chromosome 11 and detection of DNA polymorphisms. Biochem. Biophys. Res. Commun., 1986, 137(3), 1196-1204.
4. Sellar, G.C.; Jordan, S.A.; Bickmore, W.A.; Fantes, J.A.; van Heyningen, V.; Whitehead, A.S. The human serum amyloid A protein (SAA) superfamily gene cluster: mapping to chromosome 11p15.1 by physical and genetic linkage analysis. Genomics, 1994, 19(2), 221-227.
5. Woo, P.; Sipe, J.; Dinarello, C.A.; Colten, H.R. Structure of a human serum amyloid A gene and modulation of its expression in transfected L cells. J. Biol. Chem., 1987, 262(32), 15790-15795.
6. Watson, G.; Coade, S.; Woo, P. Analysis of the genomic and derived protein structure of a novel human serum amyloid A gene, SAA4. Scand. J. Immunol., 1992, 36(5), 703-712.
7. Steel, D.M.; Sellar, G.C.; Uhlar, C.M.; Simon, S.; de Beer, F.C.; Whitehead, A.S. A constitutively expressed serum amyloid A protein gene (SAA4) is closely linked to, and shares structural similarities with, an acute-phase serum amyloid A protein gene (SAA2). Genomics, 1993, 16(2), 447-454.
8. Larson, M.A.; Wei, S.H.; Weber, A.; Weber, A.T.; McDonald, T.L. Induction of human mammary-associated serum amyloid A3 expression by prolactin or lipopolysaccharide. Biochem. Biophys. Res. Commun., 2003, 301(4), 1030-1037.
9. Strachan, A.F.; Brandt, W.F.; Woo, P.; van der Westhuyzen, D.R.; Coetzee, G.A.; de Beer, M.C.; Shephard, E.G.; de Beer, F.C. Human serum amyloid A protein. The assignment of the six major isoforms to three published gene sequences and evidence for two genetic loci. J. Biol. Chem., 1989, 264(31), 18368-18373.
10. Uhlar, C.M.; Burgess, C.J.; Sharp, P.M.; Whitehead, A.S. Evolution of the serum amyloid A (SAA) protein superfamily. Genomics, 1994, 19(2), 228-235.
11. Steel, D.M.; Whitehead, A.S. The major acute phase reactants: C-reactive protein, serum amyloid P component and serum amyloid A protein. Immunol. Today, 1994, 15(2), 81-88.
12. Betts, J.C.; Cheshire, J.K.; Akira, S.; Kishimoto, T.; Woo, P. The role of NF-kappa B and NF-IL6 transactivating factors in the synergistic activation of human serum amyloid A gene expression by interleukin-1 and interleukin-6. J. Biol. Chem., 1993, 268(34), 25624-25631.
13. Edbrooke, M.R.; Burt, D.W.; Cheshire, J.K.; Woo, P. Identification of cis-acting sequences responsible for phorbol ester induction of human serum amyloid A gene expression via a nuclear factor kappaB-like transcription factor. Mol. Cell. Biol., 1989, 9(5), 1908-1916.
14. Jensen, L.E.; Whitehead, A.S. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem. J., 1998, 334(Pt 3), 489-503.
15. Ray, A.; Ray, B.K. Isolation and functional characterization of cDNA of serum amyloid A-activating factor that binds to the serum amyloid A promoter. Mol. Cell. Biol., 1998, 18(12), 7327-7335.
16. Kluve-Beckerman, B.; Drumm, M.L.; Benson, M.D. Nonexpression of the human serum amyloid A three (SAA3) gene. DNA Cell. Biol., 1991, 10(9), 651-661.
17. Whitehead, A.S.; de Beer, M.C.; Steel, D.M.; Rits, M.; Lelias, J.M.; Lane, W.S.; de Beer, F.C. Identification of novel members of the serum amyloid A protein superfamily as constitutive apolipoproteins of high density lipoprotein. J. Biol. Chem., 1992, 267(6), 3862-3867.
18. Kluve-Beckerman, B.; Dwulet, F.E.; Benson, M.D. Human serum amyloid A. Three hepatic mRNAs and the corresponding proteins in one person. J. Clin. Invest., 1988, 82(5), 1670-1675.
19. Baba, S.; Masago, S.A.; Takahashi, T.; Kasama, T.; Sugimura, H.; Tsugane, S.; Tsutsui, Y.; Shirasawa, H. A novel allelic variant of serum amyloid A, SAA1 gamma: genomic evidence, evolution, frequency, and implication as a risk factor for reactive systemic AA-amyloidosis. Hum. Mol. Genet., 1995, 4(6), 1083-1087.
20. Parmelee, D.C.; Titani, K.; Ericsson, L.H.; Eriksen, N.; Benditt, E.P.; Walsh, K.A. Amino acid sequence of amyloid-related apoprotein (apoSAA1) from human highdensity lipoprotein. Biochemistry, 1982, 21(14), 3298-3303.
21. Baba, S.; Takahashi, T.; Kasama, T.; Fujie, M.; Shirasawa, H. A novel polymorphism of human serum amyloid A protein, SAA1 gamma, is characterized by alanines at both residues 52 and 57. Arch. Biochem. Biophys., 1993, 303(2), 361-366.
22. Beach, C.M.; de Beer, M.C.; Sipe, J.D.; Loose, L.D.; de Beer, F.C. Human serum amyloid A protein. Complete amino acid sequence of a new variant. Biochem. J., 1992, 282(Pt 2), 615-620.
23. Kluve-Beckerman, B.; Malle, E.; Vitt, H.; Pfeiffer, C.; Benson, M.; Steinmetz, A. Characterization of an isoelectric focusing variant of SAA1 (ASP-72) in a family of Turkish origin. Biochem. Biophys. Res. Commun., 1991, 181(3), 1097-1102.
24. Dwulet, F.E.; Wallace, D.K.; Benson, M.D. Amino acid structures of multiple forms of amyloid-related serum protein SAA from a single individual. Biochemistry, 1988, 27(5), 1677-1682.
25. Tomita, T.; Leguchi, K.; Sawamura, T.; Maru, Y. Human serum amyloid A3 (SAA3) protein, expressed as a fusion protein with SAA2, binds the oxidized low density lipoprotein receptor. PLoS One, 2015, 10(3), e0118835.
26. Upragarin, N.; Landman, W.J.; Gaastra, W.; Gruys, E. Extrahepatic production of acute phase serum amyloid A. Histol. Histopathol., 2005, 20(4), 1295-1307.
27. McDonald, T.L.; Larson, M.A.; Mack, D.R.; Weber, A. Elevated extrahepatic expression and secretion of mammary-associated serum amyloid A 3 (M-SAA3) into colostrum. Vet. Immunol. Immunopathol., 2001, 83(3-4), 203-211.
28. Benditt, E.P.; Eriksen, N. Amyloid protein SAA is associated with high density lipoprotein from human serum. Proc. Natl. Acad. Sci. U. S. A., 1977, 74(9), 4025-4028.
29. Coetzee, G.A.; Strachan, A.F.; van der Westhuyzen, D.R.; Hoppe, H.C.; Jeenah, M.S.; de Beer, F.C. Serum amyloid A-containing human high density lipoprotein 3. Density, size, and apolipoprotein composition. J. Biol. Chem., 1986, 261(21), 9644-9651.
30. de Beer, M.C.; Yuan, T.; Kindy, M.S.; Asztalos, B.F.; Roheim, P.S.; de Beer, F.C. Characterization of constitutive human serum amyloid A protein (SAA4) as an apolipoprotein. J. Lipid Res., 1995, 36(3), 526-534.
31. Yamada, T.; Kakihara, T.; Kamishima, T.; Fukuda, T.; Kawai, T. Both acute phase and constitutive serum amyloid A are present in atherosclerotic lesions. Pathol. Int., 1996, 46(10), 797-800.
32. Yamada, T.; Miyake, N.; Itoh, K.; Igari, J. Further characterization of serum amyloid A4 as a minor acute phase reactant and a possible nutritional marker. Clin. Chem. Lab. Med., 2001, 39(1), 7-10.
33. Benditt, E.P.; Hoffman, J.S.; Eriksen, N.; Parmelee, D.C.; Walsh, K.A. SAA, an apoprotein of HDL: its structure and function. Ann. N. Y. Acad. Sci., 1982, 389, 183-189.
34. Betts, J.C.; Edbrooke, M.R.; Thakker, R.V.; Woo, P. The human acute-phase serum amyloid A gene family: structure, evolution and expression in hepatoma cells. Scand. J. Immunol., 1991, 34(4), 471-482.
35. Lu, J.; Yu, Y.; Zhu, I.; Cheng, Y.; Sun, P.D. Structural mechanism of serum amyloid A-mediated inflammatory amyloidosis. Proc. Natl. Acad. Sci. U. S. A., 2014, 111(14), 5189-5194.
36. Turnell, W.; Sarra, R.; Glover, I.D.; Baum, J.O.; Caspi, D.; Baltz, M.L.; Pepys, M.B. Secondary structure prediction of human SAA1. Presumptive identification of calcium and lipid binding sites. Mol. Biol. Med., 1986, 3(5), 387-407.
37. Uhlar, C.M.; Whitehead, A.S. Serum amyloid A, the major vertebrate acute-phase reactant. Eur. J. Biochem., 1999, 265(2), 501-523.
38. Maszota, M.; Karska, N.; Spodzieja, M.; Ciarkowski, J.; Kolodziejczyk, A.S.; Rodziewicz-Motowidlo, S.; Czaplewska, P. Structural studies of the C-terminal 19-peptide of serum amyloid A and its Pro --> Ala variants interacting with human cystatin C. J. Mol. Recognit., 2015, 28(7), 413-426.
39. Sipe, J.D.; Colten, H.R.; Goldberger, G.; Edge, M.D.; Tack, B.F.; Cohen, A.S.; Whitehead, A.S. Human serum amyloid A (SAA): biosynthesis and postsynthetic processing of preSAA and structural variants defined by complementary DNA. Biochemistry, 1985, 24(12), 2931-2936.
40. Gabay, C.; Kushner, I. Acute-phase proteins and other systemic responses to inflammation. N. Engl. J. Med., 1999, 340(6), 448-454.
41. Kushner, I. The phenomenon of the acute phase response. Ann. N. Y. Acad. Sci., 1982, 389, 39-48.
42. Sung, H.J.; Ahn, J.M.; Yoon, Y.H.; Rhim, T.Y.; Park, C.S.; Park, J.Y.; Lee, S.Y.; Kim, J.W.; Cho, J.Y. Identification and validation of SAA as a potential lung cancer biomarker and its involvement in metastatic pathogenesis of lung cancer. J. Proteome Res., 2011, 10(3), 1383-1395.
43. Urieli-Shoval, S.; Cohen, P.; Eisenberg, S.; Matzner, Y. Widespread expression of serum amyloid A in histologically normal human tissues. Predominant localization to the epithelium. J. Histochem. Cytochem., 1998, 46(12), 1377-1384.
44. Castell, J.V.; Gomez-Lechon, M.J.; David, M.; Hirano, T.; Kishimoto, T.; Heinrich, P.C. Recombinant human interleukin-6 (IL-6/BSF-2/HSF) regulates the synthesis of acute phase proteins in human hepatocytes. FEBS Lett., 1988, 232(2), 347-350.
45. Kovacevic, A.; Hammer, A.; Stadelmeyer, E.; Windischhofer, W.; Sundl, M.; Ray, A.; Schweighofer, N.; Friedl, G.; Windhager, R.; Sattler, W.; Malle, E. Expression of serum amyloid A transcripts in human bone tissues, differentiated osteoblast-like stem cells and human osteosarcoma cell lines. J. Cell. Biochem., 2008, 103(3), 994-1004.
46. Kovacevic, A.; Hammer, A.; Sundl, M.; Pfister, B.; Hrzenjak, A.; Ray, A.; Ray, B.K.; Sattler, W.; Malle, E. Expression of serum amyloid A transcripts in human trophoblast and fetal-derived trophoblast-like choriocarcinoma cells. FEBS Lett., 2006, 580(1), 161-167.
47. Moshage, H.J.; Roelofs, H.M.; van Pelt, J.F.; Hazenberg, B.P.; van Leeuwen, M.A.; Limburg, P.C.; Aarden, L.A.; Yap, S.H. The effect of interleukin-1, interleukin-6 and its interrelationship on the synthesis of serum amyloid A and C-reactive protein in primary cultures of adult human hepatocytes. Biochem. Biophys. Res. Commun., 1988, 155(1), 112-117.
48. Steel, D.M.; Donoghue, F.C.; O'Neill, R.M.; Uhlar, C.M.; Whitehead, A.S. Expression and regulation of constitutive and acute phase serum amyloid A mRNAs in hepatic and non-hepatic cell lines. Scand. J. Immunol., 1996, 44(5), 493-500.
49. Steel, D.M.; Whitehead, A.S. Heterogeneous modulation of acute-phase-reactant mRNA levels by interleukin-1 beta and interleukin-6 in the human hepatoma cell line PLC/PRF/5. Biochem. J., 1991, 277(Pt 2), 477-482.
50. Vreugdenhil, A.C.; Dentener, M.A.; Snoek, A.M.; Greve, J.W.; Buurman, W.A. Lipopolysaccharide binding protein and serum amyloid A secretion by human intestinal epithelial cells during the acute phase response. J. Immunol., 1999, 163(5), 2792-2798.
51. De Buck, M.; Gouwy, M.; Wang, J.M.; Van Snick, J.; Proost, P.; Struyf, S.; Van Damme, J. The cytokine-serum amyloid A-chemokine network. Cytokine Growth Factor Rev., 2015, (in press), doi: 10.1016/j.cytogfr.2015.12.010.
52. Sjöholm, K.; Palming, J.; Olofsson, L.E.; Gummesson, A.; Svensson, P.A.; Lystig, T.C.; Jennische, E.; Brandberg, J.; Torgerson, J.S.; Carlsson, B.; Carlsson, L.M. A microarray search for genes predominantly expressed in human omental adipocytes: adipose tissue as a major production site of serum amyloid A. J. Clin. Endocrinol. Metab., 2005, 90(4), 2233-2239.
53. Yang, R.Z.; Lee, M.J.; Hu, H.; Pollin, T.I.; Ryan, A.S.; Nicklas, B.J.; Snitker, S.; Horenstein, R.B.; Hull, K.; Goldberg, N.H.; Goldberg, A.P.; Shuldiner, A.R.; Fried, S.K.; Gong, D.W. Acute-phase serum amyloid A: an inflammatory adipokine and potential link between obesity and its metabolic complications. PLoS Med., 2006, 3(6), e287.
54. Gutfeld, O.; Prus, D.; Ackerman, Z.; Dishon, S.; Linke, R.P.; Levin, M.; Urieli-Shoval, S. Expression of serum amyloid A, in normal, dysplastic, and neoplastic human colonic mucosa: implication for a role in colonic tumorigenesis. J. Histochem. Cytochem., 2006, 54(1), 63-73.
55. O'Hara, R.; Murphy, E.P.; Whitehead, A.S.; FitzGerald, O.; Bresnihan, B. Local expression of the serum amyloid A and formyl peptide receptor-like 1 genes in synovial tissue is associated with matrix metalloproteinase production in patients with inflammatory arthritis. Arthritis Rheum., 2004, 50(6), 1788-1799.
56. Urieli-Shoval, S.; Finci-Yeheskel, Z.; Dishon, S.; Galinsky, D.; Linke, R.P.; Ariel, I.; Levin, M.; Ben-Shachar, I.; Prus, D. Expression of serum amyloid A in human ovarian epithelial tumors: implication for a role in ovarian tumorigenesis. J. Histochem. Cytochem., 2010, 58(11), 1015-1023.
57. Kumon, Y.; Suehiro, T.; Hashimoto, K.; Sipe, J.D. Dexamethasone, but not IL-1 alone, upregulates acutephase serum amyloid A gene expression and production by cultured human aortic smooth muscle cells. Scand. J. Immunol., 2001, 53(1), 7-12.
58. Liang, L.; Qu, L.; Ding, Y. Protein and mRNA characterization in human colorectal carcinoma cell lines with different metastatic potentials. Cancer Invest., 2007, 25(6), 427-434.
59. Parle-McDermott, A.; McWilliam, P.; Tighe, O.; Dunican, D.; Croke, D.T. Serial analysis of gene expression identifies putative metastasis-associated transcripts in colon tumour cell lines. Br. J. Cancer, 2000, 83(6), 725-728.
60. Thorn, C.F.; Lu, Z.Y.; Whitehead, A.S. Tissue-specific regulation of the human acute-phase serum amyloid A genes, SAA1 and SAA2, by glucocorticoids in hepatic and epithelial cells. Eur. J. Immunol., 2003, 33(9), 2630-2639.
61. Cocco, E.; Bellone, S.; El-Sahwi, K.; Cargnelutti, M.; Casagrande, F.; Buza, N.; Tavassoli, F.A.; Siegel, E.R.; Visintin, I.; Ratner, E.; Silasi, D.A.; Azodi, M.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Santin, A.D. Serum amyloid A (SAA): a novel biomarker for uterine serous papillary cancer. Br. J. Cancer, 2009, 101(2), 335-341.
62. Paret, C.; Schon, Z.; Szponar, A.; Kovacs, G. Inflammatory protein serum amyloid A1 marks a subset of conventional renal cell carcinomas with fatal outcome. Eur. Urol., 2010, 57(5), 859-866.
63. O'Hara, R.; Murphy, E.P.; Whitehead, A.S.; FitzGerald, O.; Bresnihan, B. Acute-phase serum amyloid A production by rheumatoid arthritis synovial tissue. Arthritis Res., 2000, 2(2), 142-144.
64. Kosari, F.; Parker, A.S.; Kube, D.M.; Lohse, C.M.; Leibovich, B.C.; Blute, M.L.; Cheville, J.C.; Vasmatzis, G. Clear cell renal cell carcinoma: gene expression analyses identify a potential signature for tumor aggressiveness. Clin. Cancer Res., 2005, 11(14), 5128-5139.
65. Kumon, Y.; Suehiro, T.; Hashimoto, K.; Nakatani, K.; Sipe, J.D. Local expression of acute phase serum amyloid A mRNA in rheumatoid arthritis synovial tissue and cells. J. Rheumatol., 1999, 26(4), 785-790.
66. Meek, R.L.; Urieli-Shoval, S.; Benditt, E.P. Expression of apolipoprotein serum amyloid A mRNA in human atherosclerotic lesions and cultured vascular cells: implications for serum amyloid A function. Proc. Natl. Acad. Sci. USA, 1994, 91(8), 3186-3190.
67. Urieli-Shoval, S.; Meek, R.L.; Hanson, R.H.; Eriksen, N.; Benditt, E.P. Human serum amyloid A genes are expressed in monocyte/macrophage cell lines. Am. J. Pathol., 1994, 145(3), 650-660.
68. Liang, J.S.; Sloane, J.A.; Wells, J.M.; Abraham, C.R.; Fine, R.E.; Sipe, J.D. Evidence for local production of acute phase response apolipoprotein serum amyloid A in Alzheimer's disease brain. Neurosci. Lett., 1997, 225(2), 73-76.
69. Murphy, C.L.; Wang, S.; Kestler, D.P.; Stevens, F.A.; Weiss, D.T.; Solomon, A. AA amyloidosis associated with a mutated serum amyloid A4 protein. Amyloid, 2009, 16(2), 84-88.
70. Bozinovski, S.; Uddin, M.; Vlahos, R.; Thompson, M.; McQualter, J.L.; Merritt, A.S.; Wark, P.A.; Hutchinson, A.; Irving, L.B.; Levy, B.D.; Anderson, G.P. Serum amyloid A opposes lipoxin A(4) to mediate glucocorticoid refractory lung inflammation in chronic obstructive pulmonary disease. Proc. Natl. Acad. Sci. USA, 2012, 109(3), 935-940.
71. Chen, E.S.; Song, Z.; Willett, M.H.; Heine, S.; Yung, R.C.; Liu, M.C.; Groshong, S.D.; Zhang, Y.; Tuder, R.M.; Moller, D.R. Serum amyloid A regulates granulomatous inflammation in sarcoidosis through Toll-like receptor-2. Am. J. Respir. Crit. Care Med., 2010, 181(4), 360-373.
72. Lane, A.P.; Truong-Tran, Q.A.; Myers, A.; Bickel, C.; Schleimer, R.P. Serum amyloid A, properdin, complement 3, and toll-like receptors are expressed locally in human sinonasal tissue. Am. J. Rhinol., 2006, 20(1), 117-123.
73. Yu, N.; Liu, S.; Yi, X.; Zhang, S.; Ding, Y. Serum amyloid A induces interleukin-1beta secretion from keratinocytes via the NACHT, LRR and PYD domains-containing protein 3 inflammasome. Clin. Exp. Immunol., 2015, 179(2), 344-353.
74. Poitou, C.; Divoux, A.; Faty, A.; Tordjman, J.; Hugol, D.; Aissat, A.; Keophiphath, M.; Henegar, C.; Commans, S.; Clement, K. Role of serum amyloid a in adipocytemacrophage cross talk and adipocyte cholesterol efflux. J. Clin. Endocrinol. Metab., 2009, 94(5), 1810-1817.
75. Samaras, K.; Botelho, N.K.; Chisholm, D.J.; Lord, R.V. Subcutaneous and visceral adipose tissue gene expression of serum adipokines that predict type 2 diabetes. Obesity (Silver Spring), 2010, 18(5), 884-889.
76. Chung, T.F.; Sipe, J.D.; McKee, A.; Fine, R.E.; Schreiber, B.M.; Liang, J.S.; Johnson, R.J. Serum amyloid A in Alzheimer's disease brain is predominantly localized to myelin sheaths and axonal membrane. Amyloid, 2000, 7(2), 105-110.
77. Kindy, M.S.; Yu, J.; Guo, J.T.; Zhu, H. Apolipoprotein Serum Amyloid A in Alzheimer's Disease. J. Alzheimers Dis., 1999, 1(3), 155-167.
78. Miida, T.; Yamada, T.; Seino, U.; Ito, M.; Fueki, Y.; Takahashi, A.; Kosuge, K.; Soda, S.; Hanyu, O.; Obayashi, K.; Miyazaki, O.; Okada, M. Serum amyloid A (SAA)-induced remodeling of CSF-HDL. Biochim. Biophys. Acta, 2006, 1761(4), 424-433.
79. Vallon, R.; Freuler, F.; Desta-Tsedu, N.; Robeva, A.; Dawson, J.; Wenner, P.; Engelhardt, P.; Boes, L.; Schnyder, J.; Tschopp, C.; Urfer, R.; Baumann, G. Serum amyloid A (apoSAA) expression is up-regulated in rheumatoid arthritis and induces transcription of matrix metalloproteinases. J. Immunol., 2001, 166(4), 2801-2807.
80. Nishie, A.; Masuda, K.; Otsubo, M.; Migita, T.; Tsuneyoshi, M.; Kohno, K.; Shuin, T.; Naito, S.; Ono, M.; Kuwano, M. High expression of the Cap43 gene in infiltrating macrophages of human renal cell carcinomas. Clin. Cancer Res., 2001, 7(7), 2145-2151.
81. Anthony, D.; Seow, H.J.; Uddin, M.; Thompson, M.; Dousha, L.; Vlahos, R.; Irving, L.B.; Levy, B.D.; Anderson, G.P.; Bozinovski, S. Serum amyloid A promotes lung neutrophilia by increasing IL-17A levels in the mucosa and gammadelta T cells. Am. J. Respir. Crit. Care Med., 2013, 188(2), 179-186.
82. Connolly, M.; Marrelli, A.; Blades, M.; McCormick, J.; Maderna, P.; Godson, C.; Mullan, R.; FitzGerald, O.; Bresnihan, B.; Pitzalis, C.; Veale, D.J.; Fearon, U. Acute serum amyloid A induces migration, angiogenesis, and inflammation in synovial cells in vitro and in a human rheumatoid arthritis/SCID mouse chimera model. J. Immunol., 2010, 184(11), 6427-6437.
83. de Seny, D.; Cobraiville, G.; Charlier, E.; Neuville, S.; Esser, N.; Malaise, D.; Malaise, O.; Calvo, F.Q.; Relic, B.; Malaise, M.G. Acute-phase serum amyloid A in osteoarthritis: regulatory mechanism and proinflammatory properties. PLoS One, 2013, 8(6), e66769.
84. Thorn, C.F.; Lu, Z.Y.; Whitehead, A.S. Regulation of the human acute phase serum amyloid A genes by tumour necrosis factor-alpha, interleukin-6 and glucocorticoids in hepatic and epithelial cell lines. Scand. J. Immunol., 2004, 59(2), 152-158.
85. Ray, B.K.; Ray, A. Involvement of an SAF-like transcription factor in the activation of serum amyloid A gene in monocyte/macrophage cells by lipopolysaccharide. Biochemistry, 1997, 36(15), 4662-4668.
86. Yamada, T.; Wada, A.; Itoh, K.; Igari, J. Serum amyloid A secretion from monocytic leukaemia cell line THP-1 and cultured human peripheral monocytes. Scand. J. Immunol., 2000, 52(1), 7-12.
87. Gaffney, P.M.; Barr, B.; Rowe, J.D.; Bett, C.; Drygiannakis, I.; Giannitti, F.; Trejo, M.; Ghassemian, M.; Martin, P.; Masliah, E.; Sigurdson, C.J. Protein profiling of isolated uterine AA amyloidosis causing fetal death in goats. FASEB J., 2015, 29(3), 911-919.
88. Soler, L.; Luyten, T.; Stinckens, A.; Buys, N.; Ceron, J.J.; Niewold, T.A. Serum amyloid A3 (SAA3), not SAA1 appears to be the major acute phase SAA isoform in the pig. Vet. Immunol. Immunopathol., 2011, 141(1-2), 109-115.
89. Yamada, T.; Kluve-Beckerman, B.; Liepnieks, J.J.; Benson, M.D. Fibril formation from recombinant human serum amyloid A. Biochim. Biophys. Acta, 1994, 1226(3), 323-329.
90. Wang, J.Y.; Zheng, Y.Z.; Yang, J.; Lin, Y.H.; Dai, S.Q.; Zhang, G.; Liu, W.L. Elevated levels of serum amyloid A indicate poor prognosis in patients with esophageal squamous cell carcinoma. BMC Cancer, 2012, 12, 365.
91. Rho, Y.H.; Chung, C.P.; Oeser, A.; Solus, J.; Raggi, P.; Gebretsadik, T.; Shintani, A.; Stein, C.M. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J. Rheumatol., 2008, 35(9), 1789-1794.
92. Poole, S.; Walker, D.; Gaines Das, R.E.; Gallimore, J.R.; Pepys, M.B. The first international standard for serum amyloid A protein (SAA). Evaluation in an international collaborative study. J. Immunol. Methods, 1998, 214(1-2), 1-10.
93. Marhaug, G.; Dowton, S.B. Serum amyloid A: an acute phase apolipoprotein and precursor of AA amyloid. Baillieres Clin. Rheumatol., 1994, 8(3), 553-573.
94. Glojnaric, I.; Casl, M.T.; Simic, D.; Lukac, J. Serum amyloid A protein (SAA) in colorectal carcinoma. Clin. Chem. Lab. Med., 2001, 39(2), 129-133.
95. d'Eril, G.M.; Anesi, A.; Maggiore, M.; Leoni, V. Biological variation of serum amyloid A in healthy subjects. Clin. Chem., 2001, 47(8), 1498-1499.
96. Rho, Y.H.; Chung, C.P.; Oeser, A.; Solus, J.; Asanuma, Y.; Sokka, T.; Pincus, T.; Raggi, P.; Gebretsadik, T.; Shintani, A.; Stein, C.M. Inflammatory mediators and premature coronary atherosclerosis in rheumatoid arthritis. Arthritis Rheum., 2009, 61(11), 1580-1585.
97. Cocco, E.; Bellone, S.; El-Sahwi, K.; Cargnelutti, M.; Buza, N.; Tavassoli, F.A.; Schwartz, P.E.; Rutherford, T.J.; Pecorelli, S.; Santin, A.D. Serum amyloid A: a novel biomarker for endometrial cancer. Cancer, 2010, 116(4), 843-851.
98. Fyfe, A.I.; Rothenberg, L.S.; de Beer, F.C.; Cantor, R.M.; Rotter, J.I.; Lusis, A.J. Association between serum amyloid A proteins and coronary artery disease: evidence from two distinct arteriosclerotic processes. Circulation, 1997, 96(9), 2914-2919.
99. Hijmans, W.; Sipe, J.D. Levels of the serum amyloid A protein (SAA) in normal persons of different age groups. Clin. Exp. Immunol., 1979, 35(1), 96-100.
100. Raynes, J.G.; Cooper, E.H. Comparison of serum amyloid A protein and C-reactive protein concentrations in cancer and non-malignant disease. J. Clin. Pathol., 1983, 36(7), 798-803.
101. Weinstein, P.S.; Skinner, M.; Sipe, J.D.; Lokich, J.J.; Zamcheck, N.; Cohen, A.S. Acute-phase proteins or tumour markers: the role of SAA, SAP, CRP and CEA as indicators of metastasis in a broad spectrum of neoplastic diseases. Scand. J. Immunol., 1984, 19(3), 193-198.
102. Targonska-Stepniak, B.; Majdan, M. Serum amyloid A as a marker of persistent inflammation and an indicator of cardiovascular and renal involvement in patients with rheumatoid arthritis. Mediators Inflamm., 2014, 2014, 793628.
103. Shen, C.; Sun, X.G.; Liu, N.; Mu, Y.; Hong, C.C.; Wei, W.; Zheng, F. Increased serum amyloid A and its association with autoantibodies, acute phase reactants and disease activity in patients with rheumatoid arthritis. Mol. Med. Rep., 2015, 11(2), 1528-1534.
104. Malle, E.; Sodin-Semrl, S.; Kovacevic, A. Serum amyloid A: an acute-phase protein involved in tumour pathogenesis. Cell. Mol. Life Sci., 2009, 66(1), 9-26.
105. Kimura, M.; Tomita, Y.; Imai, T.; Saito, T.; Katagiri, A.; Ohara-Mikami, Y.; Matsudo, T.; Takahashi, K. Significance of serum amyloid A on the prognosis in patients with renal cell carcinoma. Cancer, 2001, 92(8), 2072-2075.
106. Rosenthal, C.J.; Sullivan, L.M. Serum amyloid A to monitor cancer dissemination. Ann. Intern. Med., 1979, 91(3), 383-390.
107. Cunnane, G.; Grehan, S.; Geoghegan, S.; McCormack, C.; Shields, D.; Whitehead, A.S.; Bresnihan, B.; FitzGerald, O. Serum amyloid A in the assessment of early inflammatory arthritis. J. Rheumatol., 2000, 27(1), 58-63.
108. Maury, C.P.; Teppo, A.M.; Wegelius, O. Relationship between urinary sialylated saccharides, serum amyloid A protein, and C-reactive protein in rheumatoid arthritis and systemic lupus erythematosus. Ann. Rheum. Dis., 1982, 41(3), 268-271.
109. Kumon, Y.; Loose, L.D.; Birbara, C.A.; Sipe, J.D. Rheumatoid arthritis exhibits reduced acute phase and enhanced constitutive serum amyloid A protein in synovial fluid relative to serum. A comparison with C-reactive protein. J. Rheumatol., 1997, 24(1), 14-19.
110. Connolly, M.; Mullan, R.H.; McCormick, J.; Matthews, C.; Sullivan, O.; Kennedy, A.; FitzGerald, O.; Poole, A.R.; Bresnihan, B.; Veale, D.J.; Fearon, U. Acute-phase serum amyloid A regulates tumor necrosis factor alpha and matrix turnover and predicts disease progression in patients with inflammatory arthritis before and after biologic therapy. Arthritis Rheum., 2012, 64(4), 1035-1045.
111. Ostensen, M.; Marhaug, G.; Husby, G. Amyloid-related serum protein (SAA) during and after pregnancy in healthy women and women with rheumatic disease. Acta Pathol. Microbiol. Immunol. Scand. C., 1985, 93(1), 1-5.
112. Ballou, S.P.; Lozanski, F.B.; Hodder, S.; Rzewnicki, D.L.; Mion, L.C.; Sipe, J.D.; Ford, A.B.; Kushner, I. Quantitative and qualitative alterations of acute-phase proteins in healthy elderly persons. Age Ageing, 1996, 25(3), 224-230.
113. Zhao, Y.; He, X.; Shi, X.; Huang, C.; Liu, J.; Zhou, S.; Heng, C.K. Association between serum amyloid A and obesity: a meta-analysis and systematic review. Inflamm. Res., 2010, 59(5), 323-334.
114. Yamada, T.; Wada, A.; Yamaguchi, T.; Itoh, Y.; Kawai, T. Automated measurement of a constitutive isotype of serum amyloid A/SAA4 and comparison with other apolipoproteins. J. Clin. Lab. Anal., 1997, 11(6), 363-368.
115. Badolato, R.; Wang, J.M.; Murphy, W.J.; Lloyd, A.R.; Michiel, D.F.; Bausserman, L.L.; Kelvin, D.J.; Oppenheim, J.J. Serum amyloid A is a chemoattractant: induction of migration, adhesion, and tissue infiltration of monocytes and polymorphonuclear leukocytes. J. Exp. Med., 1994, 180(1), 203-209.
116. De Buck, M.; Berghmans, N.; Pörtner, N.; Vanbrabant, L.; Cockx, M.; Struyf, S.; Opdenakker, G.; Proost, P.; Van Damme, J.; Gouwy, M. Serum amyloid A1alpha induces paracrine IL-8/CXCL8 via TLR2 and directly synergizes with this chemokine via CXCR2 and formyl peptide receptor 2 to recruit neutrophils. J. Leukoc. Biol., 2015, 98(6), 1049-1060.
117. Gouwy, M.; De Buck, M.; Pörtner, N.; Opdenakker, G.; Proost, P.; Struyf, S.; Van Damme, J. Serum amyloid A chemoattracts immature dendritic cells and indirectly provokes monocyte chemotaxis by induction of cooperating CC and CXC chemokines. Eur. J. Immunol., 2015, 45(1), 101-112.
118. Lee, H.Y.; Kim, S.D.; Shim, J.W.; Lee, S.Y.; Lee, H.; Cho, K.H.; Yun, J.; Bae, Y.S. Serum amyloid A induces CCL2 production via formyl peptide receptor-like 1-mediated signaling in human monocytes. J. Immunol., 2008, 181(6), 4332-4339.
119. Xu, L.; Badolato, R.; Murphy, W.J.; Longo, D.L.; Anver, M.; Hale, S.; Oppenheim, J.J.; Wang, J.M. A novel biologic function of serum amyloid A. Induction of T lymphocyte migration and adhesion. J. Immunol., 1995, 155(3), 1184-1190.
120. Su, S.B.; Gong, W.; Gao, J.L.; Shen, W.; Murphy, P.M.; Oppenheim, J.J.; Wang, J.M. A seven-transmembrane, G protein-coupled receptor, FPRL1, mediates the chemotactic activity of serum amyloid A for human phagocytic cells. J. Exp. Med., 1999, 189(2), 395-402.
121. Furlaneto, C.J.; Campa, A. A novel function of serum amyloid A: a potent stimulus for the release of tumor necrosis factor-alpha, interleukin-1beta, and interleukin-8 by human blood neutrophil. Biochem. Biophys. Res. Commun., 2000, 268(2), 405-408.
122. He, R.; Sang, H.; Ye, R.D. Serum amyloid A induces IL-8 secretion through a G protein-coupled receptor, FPRL1/ LXA4R. Blood, 2003, 101(4), 1572-1581.
123. Ribeiro, F.P.; Furlaneto, C.J.; Hatanaka, E.; Ribeiro, W.B.; Souza, G.M.; Cassatella, M.A.; Campa, A. mRNA expression and release of interleukin-8 induced by serum amyloid A in neutrophils and monocytes. Mediators Inflamm., 2003, 12(3), 173-178.
124. Hatanaka, E.; Furlaneto, C.J.; Ribeiro, F.P.; Souza, G.M.; Campa, A. Serum amyloid A-induced mRNA expression and release of tumor necrosis factor-alpha (TNF-alpha) in human neutrophils. Immunol. Lett., 2004, 91(1), 33-37.
125. Lee, M.S.; Yoo, S.A.; Cho, C.S.; Suh, P.G.; Kim, W.U.; Ryu, S.H. Serum amyloid A binding to formyl peptide receptor-like 1 induces synovial hyperplasia and angiogenesis. J. Immunol., 2006, 177(8), 5585-5594.
126. Patel, H.; Fellowes, R.; Coade, S.; Woo, P. Human serum amyloid A has cytokine-like properties. Scand. J. Immunol., 1998, 48(4), 410-418.
127. He, R.; Shepard, L.W.; Chen, J.; Pan, Z.K.; Ye, R.D. Serum amyloid A is an endogenous ligand that differentially induces IL-12 and IL-23. J. Immunol., 2006, 177(6), 4072-4079.
128. Lee, H.Y.; Kim, M.K.; Park, K.S.; Bae, Y.H.; Yun, J.; Park, J.I.; Kwak, J.Y.; Bae, Y.S. Serum amyloid A stimulates matrix-metalloproteinase-9 upregulation via formyl peptide receptor like-1-mediated signaling in human monocytic cells. Biochem. Biophys. Res. Commun., 2005, 330(3), 989-998.
129. Migita, K.; Kawabe, Y.; Tominaga, M.; Origuchi, T.; Aoyagi, T.; Eguchi, K. Serum amyloid A protein induces production of matrix metalloproteinases by human synovial fibroblasts. Lab. Invest., 1998, 78(5), 535-539.
130. Gatt, M.E.; Urieli-Shoval, S.; Preciado-Patt, L.; Fridkin, M.; Calco, S.; Azar, Y.; Matzner, Y. Effect of serum amyloid A on selected in vitro functions of isolated human neutrophils. J. Lab. Clin. Med., 1998, 132(5), 414-420.
131. Linke, R.P.; Bock, V.; Valet, G.; Rothe, G. Inhibition of the oxidative burst response of N-formyl peptide-stimulated neutrophils by serum amyloid-A protein. Biochem. Biophys. Res. Commun., 1991, 176(3), 1100-1105.
132. Shah, C.; Hari-Dass, R.; Raynes, J.G. Serum amyloid A is an innate immune opsonin for Gram-negative bacteria. Blood, 2006, 108(5), 1751-1757.
133. Hirakura, Y.; Carreras, I.; Sipe, J.D.; Kagan, B.L. Channel formation by serum amyloid A: a potential mechanism for amyloid pathogenesis and host defense. Amyloid, 2002, 9(1), 13-23.
134. Quist, A.; Doudevski, I.; Lin, H.; Azimova, R.; Ng, D.; Frangione, B.; Kagan, B.; Ghiso, J.; Lal, R. Amyloid ion channels: a common structural link for protein-misfolding disease. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(30), 10427-10432.
135. Cai, Z.; Cai, L.; Jiang, J.; Chang, K.S.; van der Westhuyzen, D.R.; Luo, G. Human serum amyloid A protein inhibits hepatitis C virus entry into cells. J. Virol., 2007, 81(11), 6128-6133.
136. Lavie, M.; Voisset, C.; Vu-Dac, N.; Zurawski, V.; Duverlie, G.; Wychowski, C.; Dubuisson, J. Serum amyloid A has antiviral activity against hepatitis C virus by inhibiting virus entry in a cell culture system. Hepatology, 2006, 44(6), 1626-1634.
137. Derebe, M.; Zlatkov, C.; Gattu, S.; Ruhn, K.; Vaishnava, S.; Diehl, G.; MacMillan, J.; Williams, N.; Hooper, L. Serum amyloid A is a retinol binding protein that transports retinol during bacterial infection. Elife, 2014, 3: e03206.
138. Sun, L.; Zhou, H.; Zhu, Z.; Yan, Q.; Wang, L.; Liang, Q.; Ye, R.D. Ex vivo and in vitro effect of serum amyloid A in the induction of macrophage M2 markers and efferocytosis of apoptotic neutrophils. J. Immunol., 2015, 194(10), 4891-4900.
139. Cai, L.; de Beer, M.C.; de Beer, F.C.; van der Westhuyzen, D.R. Serum amyloid A is a ligand for scavenger receptor class B type I and inhibits high density lipoprotein binding and selective lipid uptake. J. Biol. Chem., 2005, 280(4), 2954-2961.
140. Kisilevsky, R.; Manley, P.N. Acute-phase serum amyloid A: perspectives on its physiological and pathological roles. Amyloid, 2012, 19(1), 5-14.
141. Connolly, M.; Veale, D.J.; Fearon, U. Acute serum amyloid A regulates cytoskeletal rearrangement, cell matrix interactions and promotes cell migration in rheumatoid arthritis. Ann. Rheum. Dis., 2011, 70(7), 1296-1303.
142. Connolly, M.; Rooney, P.R.; McGarry, T.; Maratha, A.X.; McCormick, J.; Miggin, S.M.; Veale, D.J.; Fearon, U. Acute serum amyloid A is an endogenous TLR2 ligand that mediates inflammatory and angiogenic mechanisms. Ann. Rheum. Dis., 2015, (in press).
143. Mullan, R.H.; Bresnihan, B.; Golden-Mason, L.; Markham, T.; O'Hara, R.; FitzGerald, O.; Veale, D.J.; Fearon, U. Acute-phase serum amyloid A stimulation of angiogenesis, leukocyte recruitment, and matrix degradation in rheumatoid arthritis through an NF-kappaB-dependent signal transduction pathway. Arthritis Rheum., 2006, 54(1), 105-114.
144. Aldo-Benson, M.A.; Benson, M.D. SAA suppression of immune response in vitro: evidence for an effect on T cellmacrophage interaction. J. Immunol., 1982, 128(6), 2390-2392.
145. Zimlichman, S.; Danon, A.; Nathan, I.; Mozes, G.; Shainkin-Kestenbaum, R. Serum amyloid A, an acute phase protein, inhibits platelet activation. J. Lab. Clin. Med., 1990, 116(2), 180-186.
146. Anthony, D.; McQualter, J.L.; Bishara, M.; Lim, E.X.; Yatmaz, S.; Seow, H.J.; Hansen, M.; Thompson, M.; Hamilton, J.A.; Irving, L.B.; Levy, B.D.; Vlahos, R.; Anderson, G.P.; Bozinovski, S. SAA drives proinflammatory heterotypic macrophage differentiation in the lung via CSF-1R-dependent signaling. FASEB J., 2014, 28(9), 3867-3877.
147. Sodin-Semrl, S.; Spagnolo, A.; Mikus, R.; Barbaro, B.; Varga, J.; Fiore, S. Opposing regulation of interleukin-8 and NF-kappaB responses by lipoxin A4 and serum amyloid A via the common lipoxin A receptor. Int. J. Immunopathol. Pharmacol., 2004, 17(2), 145-156.
148. Tsun, J.G.; Shiu, S.W.; Wong, Y.; Yung, S.; Chan, T.M.; Tan, K.C. Impact of serum amyloid A on cellular cholesterol efflux to serum in type 2 diabetes mellitus. Atherosclerosis, 2013, 231(2), 405-410.
149. de Beer, M.C.; Ji, A.; Jahangiri, A.; Vaughan, A.M.; de Beer, F.C.; van der Westhuyzen, D.R.; Webb, N.R. ATP binding cassette G1-dependent cholesterol efflux during inflammation. J. Lipid Res., 2011, 52(2), 345-353.
150. de Beer, M.C.; Wroblewski, J.M.; Noffsinger, V.P.; Ji, A.; Meyer, J.M.; van der Westhuyzen, D.R.; de Beer, F.C.; Webb, N.R. The Impairment of Macrophage-to-Feces Reverse Cholesterol Transport during Inflammation Does Not Depend on Serum Amyloid A. J. Lipids, 2013, 2013, 283486.
151. Stonik, J.A; Remaley, A.T.; Demosky, S.J.; Neufeld, E.B.; Bocharov, A.; Brewer, H.B. Serum amyloid A promotes ABCA1-dependent and ABCA1-independent lipid efflux from cells. Biochem. Biophys. Res. Commun., 2004, 321(4), 936-941.
152. van der Westhuyzen, D.R.; Cai, L.; de Beer, M.C.; de Beer, F.C. Serum amyloid A promotes cholesterol efflux mediated by scavenger receptor B-I. J. Biol. Chem., 2005, 280(43), 35890-35895.
153. Tam, S.P.; Flexman, A.; Hulme, J.; Kisilevsky, R. Promoting export of macrophage cholesterol: the physiological role of a major acute-phase protein, serum amyloid A 2.1. J. Lipid Res., 2002, 43(9), 1410-1420.
154. Kisilevsky, R.; Subrahmanyan, L. Serum amyloid A changes high density lipoprotein's cellular affinity. A clue to serum amyloid A's principal function. Lab. Invest., 1992, 66(6), 778-785.
155. Baranova, I.N.; Bocharov, A.V.; Vishnyakova, T.G.; Kurlander, R.; Chen, Z.; Fu, D.; Arias, I.M.; Csako, G.; Patterson, A.P.; Eggerman, T.L. CD36 is a novel serum amyloid A (SAA) receptor mediating SAA binding and SAA-induced signaling in human and rodent cells. J. Biol. Chem., 2010, 285(11), 8492-8506.
156. Hari-Dass, R.; Shah, C.; Meyer, D.J.; Raynes, J.G. Serum amyloid A protein binds to outer membrane protein A of gram-negative bacteria. J. Biol. Chem., 2005, 280(19), 18562-18567.
157. Vandooren, J.; Van den Steen, P.E.; Opdenakker, G. Biochemistry and molecular biology of gelatinase B or matrix metalloproteinase-9 (MMP-9): the next decade. Crit. Rev. Biochem. Mol. Biol., 2013, 48(3), 222-272.
158. Ather, J.L.; Ckless, K.; Martin, R.; Foley, K.L.; Suratt, B.T.; Boyson, J.E.; Fitzgerald, K.A.; Flavell, R.A.; Eisenbarth, S.C.; Poynter, M.E. Serum amyloid A activates the NLRP3 inflammasome and promotes Th17 allergic asthma in mice. J. Immunol., 2011, 187(1), 64-73.
159. Halle, A.; Hornung, V.; Petzold, G.C.; Stewart, C.R.; Monks, B.G.; Reinheckel, T.; Fitzgerald, K.A.; Latz, E.; Moore, K.J.; Golenbock, D.T. The NALP3 inflammasome is involved in the innate immune response to amyloid-beta. Nat. Immunol., 2008, 9(8), 857-865.
160. Niemi, K.; Teirila, L.; Lappalainen, J.; Rajamaki, K.; Baumann, M.H.; Oorni, K.; Wolff, H.; Kovanen, P.T.; Matikainen, S.; Eklund, K.K. Serum amyloid A activates the NLRP3 inflammasome via P2X7 receptor and a cathepsin B-sensitive pathway. J. Immunol., 2011, 186(11), 6119-6128.
161. Masters, S.L.; Dunne, A.; Subramanian, S.L.; Hull, R.L.; Tannahill, G.M.; Sharp, F.A.; Becker, C.; Franchi, L.; Yoshihara, E.; Chen, Z.; Mullooly, N.; Mielke, L.A.; Harris, J.; Coll, R.C.; Mills, K.H.; Mok, K.H.; Newsholme, P.; Nunez, G.; Yodoi, J.; Kahn, S.E.; Lavelle, E.C.; O'Neill, L.A. Activation of the NLRP3 inflammasome by islet amyloid polypeptide provides a mechanism for enhanced IL-1beta in type 2 diabetes. Nat. Immunol., 2010, 11(10), 897-904.
162. Chen, K.; Le, Y.; Liu, Y.; Gong, W.; Ying, G.; Huang, J.; Yoshimura, T.; Tessarollo, L.; Wang, J.M. A critical role for the g protein-coupled receptor mFPR2 in airway inflammation and immune responses. J. Immunol., 2010, 184(7), 3331-3335.
163. Liu, M.; Chen, K.; Yoshimura, T.; Liu, Y.; Gong, W.; Wang, A.; Gao, J.L.; Murphy, P.M.; Wang, J.M. Formylpeptide receptors are critical for rapid neutrophil mobilization in host defense against Listeria monocytogenes. Sci. Rep., 2012, 2, 786.
164. Nardelli, B.; Tiffany, H.L.; Bong, G.W.; Yourey, P.A.; Morahan, D.K.; Li, Y.; Murphy, P.M.; Alderson, R.F. Characterization of the signal transduction pathway activated in human monocytes and dendritic cells by MPIF-1, a specific ligand for CC chemokine receptor 1. J. Immunol., 1999, 162(1), 435-444.
165. Youn, B.S.; Zhang, S.M.; Broxmeyer, H.E.; Cooper, S.; Antol, K.; Fraser, M.Jr.; Kwon, B.S. Characterization of CKbeta8 and CKbeta8-1: two alternatively spliced forms of human beta-chemokine, chemoattractants for neutrophils, monocytes, and lymphocytes, and potent agonists at CC chemokine receptor 1. Blood, 1998, 91(9), 3118-3126.
166. Elagoz, A.; Henderson, D.; Babu, P.S.; Salter, S.; Grahames, C.; Bowers, L.; Roy, M.O.; Laplante, P.; Grazzini, E.; Ahmad, S.; Lembo, P.M. A truncated form of CKbeta8-1 is a potent agonist for human formyl peptidereceptor-like 1 receptor. Br. J. Pharmacol., 2004, 141(1), 37-46.
167. Le, Y.; Gong, W.; Li, B.; Dunlop, N.M.; Shen, W.; Su, S.B.; Ye, R.D.; Wang, J.M. Utilization of two seventransmembrane, G protein-coupled receptors, formyl peptide receptor-like 1 and formyl peptide receptor, by the synthetic hexapeptide WKYMVm for human phagocyte activation. J. Immunol., 1999, 163(12), 6777-6784.
168. Ying, G.; Iribarren, P.; Zhou, Y.; Gong, W.; Zhang, N.; Yu, Z.X.; Le, Y.; Cui, Y.; Wang, J.M. Humanin, a newly identified neuroprotective factor, uses the G proteincoupled formylpeptide receptor-like-1 as a functional receptor. J. Immunol., 2004, 172(11), 7078-7085.
169. Harada, M.; Habata, Y.; Hosoya, M.; Nishi, K.; Fujii, R.; Kobayashi, M.; Hinuma, S. N-Formylated humanin activates both formyl peptide receptor-like 1 and 2. Biochem. Biophys. Res. Commun., 2004, 324(1), 255-261.
170. Le, Y.; Gong, W.; Tiffany, H.L.; Tumanov, A.; Nedospasov, S.; Shen, W.; Dunlop, N.M.; Gao, J.L.; Murphy, P.M.; Oppenheim, J.J.; Wang, J.M. Amyloid (beta)42 activates a G-protein-coupled chemoattractant receptor, FPR-like-1. J. Neurosci., 2001, 21(2), RC123.
171. Tiffany, H.L.; Lavigne, M.C.; Cui, Y.H.; Wang, J.M.; Leto, T.L.; Gao, J.L.; Murphy, P.M. Amyloid-beta induces chemotaxis and oxidant stress by acting at formylpeptide receptor 2, a G protein-coupled receptor expressed in phagocytes and brain. J. Biol. Chem., 2001, 276(26), 23645-23652.
172. Rabiet, M.J.; Huet, E.; Boulay, F. Human mitochondriaderived N-formylated peptides are novel agonists equally active on FPR and FPRL1, while Listeria monocytogenesderived peptides preferentially activate FPR. Eur. J. Immunol., 2005, 35(8), 2486-2495.
173. Chen, K.; Liu, M.; Liu, Y.; Yoshimura, T.; Shen, W.; Le, Y.; Durum, S.; Gong, W.; Wang, C.; Gao, J.L.; Murphy, P.M.; Wang, J.M. Formylpeptide receptor-2 contributes to colonic epithelial homeostasis, inflammation, and tumorigenesis. J. Clin. Invest., 2013, 123(4), 1694-1704.
174. Chen, M.; Zhou, H.; Cheng, N.; Qian, F.; Ye, R.D. Serum amyloid A1 isoforms display different efficacy at Toll-like receptor 2 and formyl peptide receptor 2. Immunobiology, 2014, 219(12), 916-923.
175. Yang, D.; Chen, Q.; Schmidt, A.P.; Anderson, G.M.; Wang, J.M.; Wooters, J.; Oppenheim, J.J.; Chertov, O. LL-37, the neutrophil granule- and epithelial cell-derived cathelicidin, utilizes formyl peptide receptor-like 1 (FPRL1) as a receptor to chemoattract human peripheral blood neutrophils, monocytes, and T cells. J. Exp. Med., 2000, 192(7), 1069-1074.
176. Kurosaka, K.; Chen, Q.; Yarovinsky, F.; Oppenheim, J.J.; Yang, D. Mouse cathelin-related antimicrobial peptide chemoattracts leukocytes using formyl peptide receptor-like 1/mouse formyl peptide receptor-like 2 as the receptor and acts as an immune adjuvant. J. Immunol., 2005, 174(10), 6257-6265.
177. Christophe, T.; Karlsson, A.; Dugave, C.; Rabiet, M.J.; Boulay, F.; Dahlgren, C. The synthetic peptide Trp-Lys-Tyr-Met-Val-Met-NH2 specifically activates neutrophils through FPRL1/lipoxin A4 receptors and is an agonist for the orphan monocyte-expressed chemoattractant receptor FPRL2. J. Biol. Chem., 2001, 276(24), 21585-21593.
178. Hu, J.Y.; Le, Y.; Gong, W.; Dunlop, N.M.; Gao, J.L.; Murphy, P.M.; Wang, J.M. Synthetic peptide MMK-1 is a highly specific chemotactic agonist for leukocyte FPRL1. J. Leukoc. Biol., 2001, 70(1), 155-161.
179. Klein, C.; Paul, J.I.; Sauve, K.; Schmidt, M.M.; Arcangeli, L.; Ransom, J.; Trueheart, J.; Manfredi, J.P.; Broach, J.R.; Murphy, A.J. Identification of surrogate agonists for the human FPRL-1 receptor by autocrine selection in yeast. Nat. Biotechnol., 1998, 16(13), 1334-1337.
180. Han, S.H.; Kim, J.H.; Martin, M.; Michalek, S.M.; Nahm, M.H. Pneumococcal lipoteichoic acid (LTA) is not as potent as staphylococcal LTA in stimulating Toll-like receptor 2. Infect. Immun., 2003, 71(10), 5541-5548.
181. Lotz, S.; Aga, E.; Wilde, I.; van Zandbergen, G.; Hartung, T.; Solbach, W.; Laskay, T. Highly purified lipoteichoic acid activates neutrophil granulocytes and delays their spontaneous apoptosis via CD14 and TLR2. J. Leukoc. Biol., 2004, 75(3), 467-477.
182. Natsuka, M.; Uehara, A.; Yang, S.; Echigo, S.; Takada, H. A polymer-type water-soluble peptidoglycan exhibited both Toll-like receptor 2- and NOD2-agonistic activities, resulting in synergistic activation of human monocytic cells. Innate. Immun., 2008, 14(5), 298-308.
183. Ryu, Y.H.; Baik, J.E.; Yang, J.S.; Kang, S.S.; Im, J.; Yun, C.H.; Kim, D.W.; Lee, K.; Chung, D.K.; Ju, H.R.; Han, S.H. Differential immunostimulatory effects of Grampositive bacteria due to their lipoteichoic acids. Int. Immunopharmacol., 2009, 9(1), 127-133.
184. Takeuchi, O.; Hoshino, K.; Kawai, T.; Sanjo, H.; Takada, H.; Ogawa, T.; Takeda, K.; Akira, S. Differential roles of TLR2 and TLR4 in recognition of gram-negative and grampositive bacterial cell wall components. Immunity, 1999, 11(4), 443-451.
185. Brightbill, H.D.; Libraty, D.H.; Krutzik, S.R.; Yang, R.B.; Belisle, J.T.; Bleharski, J.R.; Maitland, M.; Norgard, M.V.; Plevy, S.E.; Smale, S.T.; Brennan, P.J.; Bloom, B.R.; Godowski, P.J.; Modlin, R.L. Host defense mechanisms triggered by microbial lipoproteins through toll-like receptors. Science, 1999, 285(5428), 732-736.
186. Dillon, S.; Agrawal, S.; Banerjee, K.; Letterio, J.; Denning, T.L.; Oswald-Richter, K.; Kasprowicz, D.J.; Kellar, K.; Pare, J.; van Dyke, T.; Ziegler, S.; Unutmaz, D.; Pulendran, B. Yeast zymosan, a stimulus for TLR2 and dectin-1, induces regulatory antigen-presenting cells and immunological tolerance. J. Clin. Invest., 2006, 116(4), 916-928.
187. Lien, E.; Sellati, T.J.; Yoshimura, A.; Flo, T.H.; Rawadi, G.; Finberg, R.W.; Carroll, J.D.; Espevik, T.; Ingalls, R.R.; Radolf, J.D.; Golenbock, D.T. Toll-like receptor 2 functions as a pattern recognition receptor for diverse bacterial products. J. Biol. Chem., 1999, 274(47), 33419-33425.
188. Sato, M.; Sano, H.; Iwaki, D.; Kudo, K.; Konishi, M.; Takahashi, H.; Takahashi, T.; Imaizumi, H.; Asai, Y.; Kuroki, Y. Direct binding of Toll-like receptor 2 to zymosan, and zymosan-induced NF-kappa B activation and TNF-alpha secretion are down-regulated by lung collectin surfactant protein A. J. Immunol., 2003, 171(1), 417-425.
189. Baek, S.H.; Seo, J.K.; Chae, C.B.; Suh, P.G.; Ryu, S.H. Identification of the peptides that stimulate the phosphoinositide hydrolysis in lymphocyte cell lines from peptide libraries. J. Biol. Chem., 1996, 271(14), 8170-8175.
190. Bae, Y.S.; Lee, H.Y.; Jo, E.J.; Kim, J.I.; Kang, H.K.; Ye, R.D.; Kwak, J.Y.; Ryu, S.H. Identification of peptides that antagonize formyl peptide receptor-like 1-mediated signaling. J. Immunol., 2004, 173(1), 607-614.
191. Forsman, H.; Andreasson, E.; Karlsson, J.; Boulay, F.; Rabiet, M.J.; Dahlgren, C. Structural characterization and inhibitory profile of formyl peptide receptor 2 selective peptides descending from a PIP2-binding domain of gelsolin. J. Immunol., 2012, 189(2), 629-637.
192. Meng, G.; Rutz, M.; Schiemann, M.; Metzger, J.; Grabiec, A.; Schwandner, R.; Luppa, P.B.; Ebel, F.; Busch, D.H.; Bauer, S.; Wagner, H.; Kirschning, C.J. Antagonistic antibody prevents toll-like receptor 2-driven lethal shocklike syndromes. J. Clin. Invest., 2004, 113(10), 1473-1481.
193. Fekonja, O.; Avbelj, M.; Jerala, R. Suppression of TLR signaling by targeting TIR domain-containing proteins. Curr. Protein Pept. Sci., 2012, 13(8), 776-788.
194. Shuto, T.; Ono, T.; Ohira, Y.; Shimasaki, S.; Mizunoe, S.; Watanabe, K.; Suico, M.A.; Koga, T.; Sato, T.; Morino, S.; Sato, K.; Kai, H. Curcumin decreases toll-like receptor-2 gene expression and function in human monocytes and neutrophils. Biochem. Biophys. Res. Commun., 2010, 398(4), 647-652.
195. Cheng, K.; Wang, X.; Zhang, S.; Yin, H. Discovery of small-molecule inhibitors of the TLR1/TLR2 complex. Angew. Chem. Int. Ed. Engl., 2012, 51(49), 12246-12249.
196. Koymans, K.J.; Feitsma, L.J.; Brondijk, T.H.; Aerts, P.C.; Lukkien, E.; Lossl, P.; van Kessel, K.P.; de Haas, C.J.; van Strijp, J.A.; Huizinga, E.G. Structural basis for inhibition of TLR2 by staphylococcal superantigen-like protein 3 (SSL3). Proc. Natl. Acad. Sci. USA, 2015, 112(35), 11018-11023.
197. Zanin-Zhorov, A.; Tal, G.; Shivtiel, S.; Cohen, M.; Lapidot, T.; Nussbaum, G.; Margalit, R.; Cohen, I.R.; Lider, O. Heat shock protein 60 activates cytokine-associated negative regulator suppressor of cytokine signaling 3 in T cells: effects on signaling, chemotaxis, and inflammation. J. Immunol., 2005, 175(1), 276-285.
198. Seyberth, T.; Voss, S.; Brock, R.; Wiesmuller, K.H.; Jung, G. Lipolanthionine peptides act as inhibitors of TLR2-mediated IL-8 secretion. Synthesis and structure-activity relationships. J. Med. Chem., 2006, 49(5), 1754-1765.
199. Badolato, R.; Oppenheim, J.J. Role of cytokines, acutephase proteins, and chemokines in the progression of rheumatoid arthritis. Semin. Arthritis Rheum., 1996, 26(2), 526-538.
200. Hatanaka, E.; Monteagudo, P.T.; Marrocos, M.S.; Campa, A. Interaction between serum amyloid A and leukocytes - a possible role in the progression of vascular complications in diabetes. Immunol. Lett., 2007, 108(2), 160-166.
201. Jahangiri, A.; Wilson, P.G.; Hou, T.; Brown, A.; King, V.L.; Tannock, L.R. Serum amyloid A is found on ApoBcontaining lipoproteins in obese humans with diabetes. Obesity (Silver Spring), 2013, 21(5), 993-996.
202. Marzi, C.; Huth, C.; Herder, C.; Baumert, J.; Thorand, B.; Rathmann, W.; Meisinger, C.; Wichmann, H.E.; Roden, M.; Peters, A.; Grallert, H.; Koenig, W.; Illig, T. Acute-phase serum amyloid A protein and its implication in the development of type 2 diabetes in the KORA S4/F4 study. Diabetes Care, 2013, 36(5), 1321-1326.
203. King, V.L.; Thompson, J.; Tannock, L.R. Serum amyloid A in atherosclerosis. Curr. Opin. Lipidol., 2011, 22(4), 302-307.
204. Lee, H.Y.; Kim, S.D.; Baek, S.H.; Choi, J.H.; Bae, Y.S. Role of formyl peptide receptor 2 on the serum amyloid A-induced macrophage foam cell formation. Biochem. Biophys. Res. Commun., 2013, 433(2), 255-259.
205. Thompson, J.C.; Jayne, C.; Thompson, J.; Wilson, P.G.; Yoder, M.H.; Webb, N.; Tannock, L.R. A brief elevation of serum amyloid A is sufficient to increase atherosclerosis. J. Lipid Res., 2015, 56(2), 286-293.
206. Wilson, P.G.; Thompson, J.C.; Webb, N.R.; de Beer, F.C.; King, V.L.; Tannock, L.R. Serum amyloid A, but not C-reactive protein, stimulates vascular proteoglycan synthesis in a pro-atherogenic manner. Am. J. Pathol., 2008, 173(6), 1902-1910.
207. Bozinovski, S.; Hutchinson, A.; Thompson, M.; Macgregor, L.; Black, J.; Giannakis, E.; Karlsson, A.S.; Silvestrini, R.; Smallwood, D.; Vlahos, R.; Irving, L.B.; Anderson, G.P. Serum amyloid A is a biomarker of acute exacerbations of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2008, 177(3), 269-278.
208. Hansen, M.J.; Chan, S.P.; Langenbach, S.Y.; Dousha, L.F.; Jones, J.E.; Yatmaz, S.; Seow, H.J.; Vlahos, R.; Anderson, G.P.; Bozinovski, S. IL-17A and serum amyloid A are elevated in a cigarette smoke cessation model associated with the persistence of pigmented macrophages, neutrophils and activated NK cells. PLoS One, 2014, 9(11), e113180.
209. Biran, H.; Friedman, N.; Neumann, L.; Pras, M.; Shainkin-Kestenbaum, R. Serum amyloid A (SAA) variations in patients with cancer: correlation with disease activity, stage, primary site, and prognosis. J. Clin. Pathol., 1986, 39(7), 794-797.
210. Lee, J.M.; Kim, E.K.; Seo, H.; Jeon, I.; Chae, M.J.; Park, Y.J.; Song, B.; Kim, Y.S.; Kim, Y.J.; Ko, H.J.; Kang, C.Y. Serum amyloid A3 exacerbates cancer by enhancing the suppressive capacity of myeloid-derived suppressor cells via TLR2-dependent STAT3 activation. Eur. J. Immunol., 2014, 44(6), 1672-1684.
211. Nguyen, K.D.; Macaubas, C.; Truong, P.; Wang, N.; Hou, T.; Yoon, T.; Mellins, E.D. Serum amyloid A induces mitogenic signals in regulatory T cells via monocyte activation. Mol. Immunol., 2014, 59(2), 172-179.
212. Chambers, R.E.; Stross, P.; Barry, R.E.; Whicher, J.T. Serum amyloid A protein compared with C-reactive protein, alpha 1-antichymotrypsin and alpha 1-acid glycoprotein as a monitor of inflammatory bowel disease. Eur. J. Clin. Invest., 1987, 17(5), 460-467.
213. Niederau, C.; Backmerhoff, F.; Schumacher, B.; Niederau, C. Inflammatory mediators and acute phase proteins in patients with Crohn's disease and ulcerative colitis. Hepatogastroenterology, 1997, 44(13), 90-107.
214. Westermark, G.T.; Fandrich, M.; Westermark, P. AA amyloidosis: pathogenesis and targeted therapy. Annu. Rev. Pathol., 2015, 10, 321-344.
215. Yakar, S.; Livneh, A.; Kaplan, B.; Pras, M. The molecular basis of reactive amyloidosis. Semin. Arthritis Rheum., 1995, 24(4), 255-261.
216. Chambers, R.E.; MacFarlane, D.G.; Whicher, J.T.; Dieppe, P.A. Serum amyloid-A protein concentration in rheumatoid arthritis and its role in monitoring disease activity. Ann. Rheum. Dis., 1983, 42(6), 665-667.
217. Sukenik, S.; Henkin, J.; Zimlichman, S.; Skibin, A.; Neuman, L.; Pras, M.; Horowitz, J.; Shainkin-Kestenbaum, R. Serum and synovial fluid levels of serum amyloid A protein and C-reactive protein in inflammatory and noninflammatory arthritis. J. Rheumatol., 1988, 15(6), 942-945.
218. Fried, S.K.; Bunkin, D.A.; Greenberg, A.S. Omental and subcutaneous adipose tissues of obese subjects release interleukin-6: depot difference and regulation by glucocorticoid. J. Clin. Endocrinol. Metab., 1998, 83(3), 847-850.
219. Hotamisligil, G.S.; Shargill, N.S.; Spiegelman, B.M. Adipose expression of tumor necrosis factor-alpha: direct role in obesity-linked insulin resistance. Science, 1993, 259(5091), 87-91.
220. Kumon, Y.; Suehiro, T.; Itahara, T.; Ikeda, Y.; Hashimoto, K. Serum amyloid A protein in patients with non-insulindependent diabetes mellitus. Clin. Biochem., 1994, 27(6), 469-473.
221. Kumon, Y.; Hosokawa, T.; Suehiro, T.; Ikeda, Y.; Sipe, J.D.; Hashimoto, K. Acute-phase, but not constitutive serum amyloid A (SAA) is chemotactic for cultured human aortic smooth muscle cells. Amyloid, 2002, 9(4), 237-241.
222. Wang, H.; Bai, J.; Ding, M.; Liu, W.; Xu, R.; Zhang, J.; Shi, J.; Li, H. Interleukin-17A contributes to the expression of serum amyloid A in chronic rhinosinusitis with nasal polyps. Eur. Arch. Otorhinolaryngol., 2013, 270(6), 1867-1872.
223. Hershkoviz, R.; Preciado-Patt, L.; Lider, O.; Fridkin, M.; Dastych, J.; Metcalfe, D.D.; Mekori, Y.A. Extracellular matrix-anchored serum amyloid A preferentially induces mast cell adhesion. Am. J. Physiol., 1997, 273(1 Pt 1), C179-C187.
224. Biro, L.; Domjan, G.; Falus, A.; Jakab, L.; Cseh, K.; Kalabay, L.; Tarkovacs, G.; Tresch, J.; Malle, E.; Kramer, J.; Prohaszka, Z.; Jako, J.; Fust, G.; Csaszar, A. Cytokine regulation of the acute-phase protein levels in multiple myeloma. Eur. J. Clin. Invest., 1998, 28(8), 679-686.
225. Chan, D.C.; Chen, C.J.; Chu, H.C.; Chang, W.K.; Yu, J.C.; Chen, Y.J.; Wen, L.L.; Huang, S.C.; Ku, C.H.; Liu, Y.C.; Chen, J.H. Evaluation of serum amyloid A as a biomarker for gastric cancer. Ann. Surg. Oncol., 2007, 14(1), 84-93.
226. Ancsin, J.B.; Kisilevsky, R. The heparin/heparan sulfatebinding site on apo-serum amyloid A. Implications for the therapeutic intervention of amyloidosis. J. Biol. Chem., 1999, 274(11), 7172-7181.
227. Landskron, G.; De la Fuente, M.; Thuwajit, P.; Thuwajit, C.; Hermoso, M.A. Chronic inflammation and cytokines in the tumor microenvironment. J. Immunol. Res., 2014, 2014, 149185.
228. Svatikova, A.; Wolk, R.; Shamsuzzaman, A.S.; Kara, T.; Olson, E.J.; Somers, V.K. Serum amyloid A in obstructive sleep apnea. Circulation, 2003, 108(12), 1451-1454.
229. Levin, M.; Pras, M.; Franklin, E.C. Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component. J. Exp. Med., 1973, 138(2), 373-380.
230. van der Hilst, J.C. Recent insights into the pathogenesis of type AA amyloidosis. Sci. World J., 2011, 11, 641-650.
231. Cazeneuve, C.; Ajrapetyan, H.; Papin, S.; Roudot-Thoraval, F.; Genevieve, D.; Mndjoyan, E.; Papazian, M.; Sarkisian, A.; Babloyan, A.; Boissier, B.; Duquesnoy, P.; Kouyoumdjian, J.C.; Girodon-Boulandet, E.; Grateau, G.; Sarkisian, T.; Amselem, S. Identification of MEFVindependent modifying genetic factors for familial Mediterranean fever. Am. J. Hum. Genet., 2000, 67(5), 1136-1143.
232. Lundmark, K.; Westermark, G.T.; Nystrom, S.; Murphy, C.L.; Solomon, A.; Westermark, P. Transmissibility of systemic amyloidosis by a prion-like mechanism. Proc. Natl. Acad. Sci. U. S. A., 2002, 99(10), 6979-6984.
233. Murakami, T.; Inoshima, Y.; Ishiguro, N. Systemic AA amyloidosis as a prion-like disorder. Virus Res., 2015, 207, 76-81.
234. Elimova, E.; Kisilevsky, R.; Szarek, W.A.; Ancsin, J.B. Amyloidogenesis recapitulated in cell culture: a peptide inhibitor provides direct evidence for the role of heparan sulfate and suggests a new treatment strategy. FASEB J., 2004, 18(14), 1749-1751.
235. Li, J.P.; Galvis, M.L.; Gong, F.; Zhang, X.; Zcharia, E.; Metzger, S.; Vlodavsky, I.; Kisilevsky, R.; Lindahl, U. In vivo fragmentation of heparan sulfate by heparanase overexpression renders mice resistant to amyloid protein A amyloidosis. Proc. Natl. Acad. Sci. U. S. A., 2005, 102(18), 6473-6477.
236. Pinney, J.H.; Lachmann, H.J. Systemic AA amyloidosis. Subcell. Biochem., 2012, 65, 541-564.
237. Liang, J.S.; Sipe, J.D. Recombinant human serum amyloid A (apoSAAp) binds cholesterol and modulates cholesterol flux. J. Lipid Res., 1995, 36(1), 37-46.
238. Rampart, M.; Van Damme, J.; Zonnekeyn, L.; Herman, A.G. Granulocyte chemotactic protein/interleukin-8 induces plasma leakage and neutrophil accumulation in rabbit skin. Am. J. Pathol., 1989, 135(1), 21-25.
239. Sirisinha, S. The pleiotropic role of vitamin A in regulating mucosal immunity. Asian Pac. J. Allergy Immunol., 2015, 33(2), 71-89.
240. Sozzani, S.; Del Prete, A. Chemokines as relay signals in human dendritic cell migration: serum amyloid A kicks off chemotaxis. Eur. J. Immunol., 2015, 45(1), 40-43.
241. Thorn, C.F.; Whitehead, A.S. Differential glucocorticoid enhancement of the cytokine-driven transcriptional activation of the human acute phase serum amyloid A genes, SAA1 and SAA2. J. Immunol., 2002, 169(1), 399-406.
242. Christenson, K.; Björkman, L.; Ahlin, S.; Olsson, M.; Sjöholm, K.; Karlsson, A.; Bylund, J. Endogenous acute phase serum amyloid A lacks pro-inflammatory activity, contrasting the two recombinant variants that activate human neutrophils through different receptors. Front. Immunol., 2013, 4, 92.
243. van den Brand, B.; Waterborg, C.; van den Berg, W.; van de Loo, F. Is the serum amyloid A we use really serum amyloid A? Comment on the article by Connolly et al. Arthritis Rheum., 2013, 65(1), 283-284.
244. Björkman, L.; Raynes, J.G.; Shah, C.; Karlsson, A.; Dahlgren, C.; Bylund, J. The proinflammatory activity of recombinant serum amyloid A is not shared by the endogenous protein in the circulation. Arthritis Rheum., 2010, 62(6), 1660-1665.
245. Lammermann, T.; Afonso, P.V.; Angermann, B.R.; Wang, J.M.; Kastenmuller, W.; Parent, C.A.; Germain, R.N. Neutrophil swarms require LTB4 and integrins at sites of cell death in vivo. Nature, 2013, 498(7454), 371-375.
246. Liu, M.; Chen, K.; Yoshimura, T.; Liu, Y.; Gong, W.; Le, Y.; Gao, J.L.; Zhao, J.; Wang, J.M.; Wang, A. Formylpeptide receptors mediate rapid neutrophil mobilization to accelerate wound healing. PLoS One, 2014, 9(6), e90613.